Headquartered in Boston, MA Fiscal year ends December NASDAQ: VRTX vrtx.com
Vertex Pharmaceuticals is a global biotechnology company that discovers, develops and commercializes medicines for serious diseases.
Marketed products:
- **Cystic fibrosis:** its CFTR modulator franchise (TRIKAFTA/KAFTRIO, ALYFTREK, KALYDECO, ORKAMBI, SYMDEKO/SYMKEVI) can treat about 95% of people with CF in core markets and is available in more than 65 countries. It remains the bulk of revenue.
- **CASGEVY:** a CRISPR/Cas9 gene-edited cell therapy for severe sickle cell disease and transfusion-dependent beta thalassemia, approved in 36 countries.
- **JOURNAVX (suzetrigine):** a first-in-class non-opioid NaV1.8 inhibitor for moderate-to-severe acute pain in the U.S.
- **PALSONIFY (paltusotine):** an oral SST2 agonist for acromegaly, added through the roughly $10.0 billion acquisition of Crinetics Pharmaceuticals completed in September 2026. It establishes a rare endocrine franchise.
Pipeline:
- povetacicept for IgA nephropathy (FDA action date November 30, 2026), primary membranous nephropathy and generalized myasthenia gravis;
- inaxaplin for APOL1-mediated kidney disease;
- suzetrigine and VX-993 for diabetic peripheral neuropathy;
- atumelnant for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome;
- VX-017 stem cell-derived islet cell therapy for type 1 diabetes;
- VX-407 for ADPKD;
- VX-670 for myotonic dystrophy type 1;
- next-generation CFTR correctors. Updated
The beat was narrow, but management raised full-year revenue guidance to $13.15 billion to $13.25 billion as CASGEVY, JOURNAVX and newly acquired PALSONIFY start carrying weight beyond cystic fibrosis. An FDA decision on povetacicept in IgA nephropathy lands November 30, which would make nephrology the fifth commercial franchise.
With the potential povetacicept approval in IgAN coming later this month, we are well positioned to establish nephrology as our fifth commercial franchise and expand the reach of our transformative medicines to even more patients.
An FDA decision on povetacicept lands this month, and Kewalramani is already framing kidney disease as Vertex's fifth commercial franchise after cystic fibrosis. The stock has slipped 5.95% since the earnings call, so the approval carries the burden of restoring the growth story.
Vertex Pharmaceuticals closed at $558.88, a fresh 52-week high and 0.16% above the September 3 peak. The $141.7 billion biotech has now reclaimed the top of its range after a two-month stretch spent trading closer to $500.
A fresh board seat at a $135.6 billion biotech means another vote on how Vertex spends its cash as pipeline catalysts line up behind the cystic fibrosis franchise. Brennan's future Form 4s now become a live signal on insider conviction heading into those readouts.
A 4.1% drop to $486.60 lops roughly $5 billion off a $123.3 billion biotech in a single session, a rare one-day swing for a name that usually trades like a defensive compounder. Worth watching whether it holds this level into the close.
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) reports third-quarter results on Nov. 2. Cystic fibrosis still pays the bills, but I’ll be watching whether CASGEVY and JOURNAVX stay on pace for management’s…
Rich Duprey CRISPR Therapeutics owns the only approved gene therapy of its kind, yet the stock sits far below where Wall Street thinks it belongs. One analyst sees a path to gains that would…
Biotech just staged one of its sharpest reversals in years, and whether you caught it or completely missed it, the same uncomfortable question now sits in front of every portfolio: does the…
Vertex Pharmaceuticals drops its Q2 2026 results tonight with a $10 billion acquisition just closed, a blockbuster pain drug launch in full swing, and analysts watching one kidney disease drug that could…
Thomas Richmond Crinetics Pharmaceuticals (NASDAQ:CRNX) shares have climbed 99% just this week, from $42.03 at Monday’s close, to $83.54 earlier today. The simple reason: Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) agreed to acquire…
CNBC’s Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter. Instead, he highlighted a group he says has quietly become the market’s leader. “There is a move in biotech…
On CNBC’s Mad Dash segment on Monday, July 6, 2026, Jim Cramer made one of his most bullish biotech calls in years, arguing that the sector could be entering a new wave…
The death crosses flashing on both Hershey (NYSE: HSY | HSY Price Prediction) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring. Analyst consensus on…
Vertex Pharmaceuticals (NASDAQ:VRTX | VRTX Price Prediction) screens as a long-duration compounder because it sits on a global monopoly in cystic fibrosis therapies that generates substantial free cash, while Wall Street prices…
Alex Sirois If you’re looking to diversify outside of AI, especially as AI investors look to trim their winners to save up for that mega-cap AI IPO boom on the horizon, with SpaceX leading…
Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR…
Saudi Aramco CEO Amin Nasser did not mince words on Tuesday. Speaking to reporters on an earnings call, he said: “The Iran war will have catastrophic consequences for the world’s oil market.”…
Pre-Market Futures: The futures are trading higher this morning after another stellar day across Wall Street on Tuesday, as all the major indices once again ended higher and continue to print new…
Turning a $10,000 investment into $1 million represents a financial dream for many — a 100x return that would require an annualized growth rate of approximately 63% over a decade. This level…
Buy-and-hold investing is a time-tested strategy that rewards patience and discipline. By owning high-quality stocks for at least three to five years, preferably a decade or more, investors can harness the power…
Vertex Pharmaceuticals is a global biotechnology company that discovers, develops and commercializes medicines for serious diseases.
24/7 Wall St.'s 12-month price target for VRTX is $678.74, rated Buy. The Wall Street consensus target is $571.46. VRTX price prediction →
